Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. develops clinical-stage therapies for autoimmune diseases and cancer, with a pipeline centered on T cell engagers and targeted oncology programs. Recurring news includes updates on CLN-978, a CD19xCD3 T cell engager for autoimmune diseases; velinotamig, a BCMAxCD3 program; CLN-049, a FLT3xCD3 bispecific T cell engager for relapsed or refractory AML and MDS; and zipalertinib for EGFR exon 20 insertion-mutated non-small cell lung cancer.
Company announcements commonly cover clinical data presentations, regulatory submissions and FDA communications, portfolio prioritization, collaborations involving zipalertinib, quarterly financial results, cash runway commentary and healthcare investor conference participation.
Cullinan Management, a biopharmaceutical company, has announced the pricing of its upsized initial public offering of 11,900,000 shares at $21.00 each, aiming to raise approximately $249.9 million before expenses. The shares will begin trading on The Nasdaq under the symbol CGEM on January 8, 2021, with the offering expected to close on January 12, 2021. The company focuses on developing targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.